 |
NEWS RELEASE
THESIS CHEMISTRY TO PROVIDE PARTNERED CHEMICAL DEVELOPMENT ON AN ANTI-ARRHYTHMIC PRODUCT FOR ACADEMIC PHARMACEUTICALS
MISSISSAUGA, ONTARIO—November 25, 2002—Thesis Chemistry Inc., a provider of innovative Chemistry, Manufacturing and Control (CMC) development services to the pharmaceutical industry, has entered into an agreement with Academic Pharmaceuticals, Inc. of Lake Bluff, IL, USA. Under the agreement, Thesis Chemistry will provide chemical process development and scale-up preparations of an anti-arrhythmic drug under development at Academic Pharmaceuticals. Providing the initial development effort supports moving forward with clinical studies and commercial feasibility, Thesis Chemistry will be granted a CMC development agreement and worldwide manufacturing rights to the bulk drug substance.
"Our partnership with Academic Pharmaceuticals is an excellent example of how Thesis Chemistry can bring chemical innovation and value to our pharmaceutical customers from research to commercialization," says Dr. John R. Peterson, Chairman and Chief Executive Officer of Thesis Chemistry. "The process to produce this anti-arrhythmic agent is still exploratory and without significant improvement the commercial potential of this life saving drug could be severely limited. Thesis Chemistry intends to deliver the technical innovation to make this an economically viable process, and then capture that innovation through manufacture of the bulk drug substance for Academic Pharmaceuticals on a world-wide basis."
"We are very excited to partner with Thesis Chemistry on this development product", says John C. Somberg, MD, President of Academic Pharmaceuticals. "Through this unique partnership Academic Pharmaceuticals will be able to simultaneously move more drug candidates forward without giving up its marketing and development rights to the product."
Thesis Chemistry powers pharmaceutical research and development through creative chemistry. Founded in 2002 as a private Canadian corporation, the Company manages and offers the highest-quality technical capabilities in support of CMC development of small-molecule drugs. Through core expertise in process and analytical chemistry and familiarity with the current regulatory requirements of drug development, Thesis Chemistry significantly reduces the time and cost of chemical development, while delivering innovative process solutions for the economical commercial manufacture of Active Pharmaceutical Ingredients (APIs). By linking specialized processing technologies and capabilities available through a network of industry partners, Thesis Chemistry brings the right technology and development capability to a project at the right time. Thesis Chemistry supports CMC development with supplies of pre-clinical and clinical API's, process design, development and optimization, analytical testing and stability, commercial API manufacture and the identification of reliable and low-cost sources of raw materials and process intermediates.
Academic Pharmaceuticals is a privately-held biopharmaceutical company that targets the development of new pharmaceutical products through improvements in the safety and/or efficacy of existing drugs. The company has advanced Amio-Aqueous IV into Phase III clinical trials for the treatment of arrhythmia and has a number of other products in pre-clinical development.
|
|
|
